Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022
Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. Most cases of HCC result either from infection with viral hepatitis (Hepatitis B or C), metabolic toxins such as alcohol or aflatoxin, conditions such as hemochromatosis and alpha-deficiency 1-antitrypsin, or NASH.
As per RNCOS report “Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022” the global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.
Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.
Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.
As per our research, Nexavar is the only approved targeted drug for the advance hepatocellular carcinoma as of now; with the exception of Miripla approved only in Japan. However, there are molecules in the Phase III clinical development as first-line and second-line treatments, promising to influence the competitive landscape over the next two to three years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America is accounted for the largest share. In addition, Asia-Pacific is projected to be the fastest growing region due to the increasing incidence of chronic disorders, such as cancer, diabetes, hepatitis infections, and others.
Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.
As per RNCOS report “Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022” the global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.
Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.
Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.
As per our research, Nexavar is the only approved targeted drug for the advance hepatocellular carcinoma as of now; with the exception of Miripla approved only in Japan. However, there are molecules in the Phase III clinical development as first-line and second-line treatments, promising to influence the competitive landscape over the next two to three years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America is accounted for the largest share. In addition, Asia-Pacific is projected to be the fastest growing region due to the increasing incidence of chronic disorders, such as cancer, diabetes, hepatitis infections, and others.
Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. HEPATOCELLULAR CARCINOMA- AN INTRODUCTION
3.1 Etiology and Epidemiology of Hepatocellular Carcinoma
3.2 Risk Factors
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Incidences of Chronic Liver Diseases
4.1.2 Increasing Aging Population
4.1.3 Increasing R&D Investments
4.2 Challenges
4.2.1 Unsuccessful Clinical Trials
4.2.2 Stringent Regulatory Challenges
4.3 Opportunities
4.3.1 Advancement of Cancer Drug Research
4.3.2 Personalized Drug
5. GLOBAL HEPATOCELLULAR CARCINOMA DRUG MARKET OUTLOOK 2022
6. GLOBAL HEPATOCELLULAR CARCINOMA DRUG PIPELINE ANALYSIS
6.1 Hepatocellular Carcinoma Drug Pipeline by Industries
6.1.1 By Clinical Phase
6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations
6.2.1 By Clinical Phase
7. MARKET SEGMENT BY GEOGRAPHY
7.1 North America
7.2 Europe
7.3 Asia Pacific
8. COMPANY PROFILES
8.1 Pfizer Inc.
8.2 Eli Lilly and Company
8.3 Alnylam Pharmaceuticals, Inc.
8.4 Exelixis, Inc.
8.5 ArQule, Inc.
8.6 Polaris Pharmaceuticals, Inc. (PPI)
8.7 Bayer AG
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Bristol-Mayers Squibb
8.10 Celsion, Inc.
2. RESEARCH METHODOLOGY
3. HEPATOCELLULAR CARCINOMA- AN INTRODUCTION
3.1 Etiology and Epidemiology of Hepatocellular Carcinoma
3.2 Risk Factors
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Incidences of Chronic Liver Diseases
4.1.2 Increasing Aging Population
4.1.3 Increasing R&D Investments
4.2 Challenges
4.2.1 Unsuccessful Clinical Trials
4.2.2 Stringent Regulatory Challenges
4.3 Opportunities
4.3.1 Advancement of Cancer Drug Research
4.3.2 Personalized Drug
5. GLOBAL HEPATOCELLULAR CARCINOMA DRUG MARKET OUTLOOK 2022
6. GLOBAL HEPATOCELLULAR CARCINOMA DRUG PIPELINE ANALYSIS
6.1 Hepatocellular Carcinoma Drug Pipeline by Industries
6.1.1 By Clinical Phase
6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations
6.2.1 By Clinical Phase
7. MARKET SEGMENT BY GEOGRAPHY
7.1 North America
7.2 Europe
7.3 Asia Pacific
8. COMPANY PROFILES
8.1 Pfizer Inc.
8.2 Eli Lilly and Company
8.3 Alnylam Pharmaceuticals, Inc.
8.4 Exelixis, Inc.
8.5 ArQule, Inc.
8.6 Polaris Pharmaceuticals, Inc. (PPI)
8.7 Bayer AG
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Bristol-Mayers Squibb
8.10 Celsion, Inc.
LIST OF FIGURES:
Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050
Figure 5-1: Global - Hepatocellular Carcinoma Drug Market, (Billion US$), 2016 & 2022
Figure 6-1: Global - Hepatocellular Carcinoma Companies Drug Pipeline, by Clinical Phase, (%) 2016
Figure 6-2: Global - Hepatocellular Carcinoma Research Organization Drug Pipeline by Clinical Phase, (%), 2016
Figure 7-1: Global - Hepatocellular Carcinoma Drug Market by Geography (%), 2016
Figure 7-2: North America - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-3: Europe - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-4: Asia Pacific - Hepatocellular Carcinoma Drug Market (Billion US$), 2016 & 2022
Figure 8-1: Pfizer Inc. - Revenue by Business Segments (%), 2016
Figure 8-2: Pfizer Inc. - Revenue by Geography (%), 2016
Figure 8-3: Eli Lilly and Company - Revenue by Business Segments (%), 2016
Figure 8-4: Eli Lilly and Company - Revenue by Geography (%), 2016
Figure 8-5: Bayer AG - Revenue by Business Segments (%), 2016
Figure 8-6: Bayer AG - Revenue by Geography (%), 2016
Figure 8-7: Teva Pharmaceutical Industries Ltd. - Revenue by Business Segments (%), 2016
Figure 8-8: Teva Pharmaceutical industries Ltd. - Revenue by Geography (%), 2016
Figure 8-9: Bristol-Mayers Squibb - Revenue by Geography (%), 2016
Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050
Figure 5-1: Global - Hepatocellular Carcinoma Drug Market, (Billion US$), 2016 & 2022
Figure 6-1: Global - Hepatocellular Carcinoma Companies Drug Pipeline, by Clinical Phase, (%) 2016
Figure 6-2: Global - Hepatocellular Carcinoma Research Organization Drug Pipeline by Clinical Phase, (%), 2016
Figure 7-1: Global - Hepatocellular Carcinoma Drug Market by Geography (%), 2016
Figure 7-2: North America - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-3: Europe - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-4: Asia Pacific - Hepatocellular Carcinoma Drug Market (Billion US$), 2016 & 2022
Figure 8-1: Pfizer Inc. - Revenue by Business Segments (%), 2016
Figure 8-2: Pfizer Inc. - Revenue by Geography (%), 2016
Figure 8-3: Eli Lilly and Company - Revenue by Business Segments (%), 2016
Figure 8-4: Eli Lilly and Company - Revenue by Geography (%), 2016
Figure 8-5: Bayer AG - Revenue by Business Segments (%), 2016
Figure 8-6: Bayer AG - Revenue by Geography (%), 2016
Figure 8-7: Teva Pharmaceutical Industries Ltd. - Revenue by Business Segments (%), 2016
Figure 8-8: Teva Pharmaceutical industries Ltd. - Revenue by Geography (%), 2016
Figure 8-9: Bristol-Mayers Squibb - Revenue by Geography (%), 2016
LIST OF TABLES:
Table 5-1: Global - Drugs with Orphan Drugs Status for Hepatocellular Carcinoma
Table 6-1: Global - Hepatocellular Carcinoma Drug in Pipeline by Companies
Table 6-2: Global - Hepatocellular Carcinoma Drug in Pipeline by Research Organization
Table 8-1: Pfizer Inc. - Financials (Million US$), 2014-2016
Table 8-2: Eli Lilly and Company - Financials (Billion US$), 2014-2016
Table 8-3: Alnylam Pharmaceuticals, Inc. - Financials (Billion US$), 2014-2016
Table 8-4: Exelixis, Inc. - Financials (Billion US$), 2014-2016
Table 8-5: Arqule - Financials (Billion US$), 2014-2016
Table 8-6: Bayer AG - Financials (Million US$), 2014-2016
Table 8-7: Teva Pharmaceutical Industries ltd. - Financials (Million US$), 2014-2016
Table 8-8: Bristol-Mayers Squibb - Financials (Billion US$), 2014-2016
Table 5-1: Global - Drugs with Orphan Drugs Status for Hepatocellular Carcinoma
Table 6-1: Global - Hepatocellular Carcinoma Drug in Pipeline by Companies
Table 6-2: Global - Hepatocellular Carcinoma Drug in Pipeline by Research Organization
Table 8-1: Pfizer Inc. - Financials (Million US$), 2014-2016
Table 8-2: Eli Lilly and Company - Financials (Billion US$), 2014-2016
Table 8-3: Alnylam Pharmaceuticals, Inc. - Financials (Billion US$), 2014-2016
Table 8-4: Exelixis, Inc. - Financials (Billion US$), 2014-2016
Table 8-5: Arqule - Financials (Billion US$), 2014-2016
Table 8-6: Bayer AG - Financials (Million US$), 2014-2016
Table 8-7: Teva Pharmaceutical Industries ltd. - Financials (Million US$), 2014-2016
Table 8-8: Bristol-Mayers Squibb - Financials (Billion US$), 2014-2016
